Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Sponsor
Sun Yat-sen University
Study ID
NCT04606108
Phase
PHASE2
Status
Unknown

Conditions

  • Soft Tissue Sarcoma

Eligibility Criteria

Sex
ALL
Age
14 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a open-lable , single arm，single center, phase II clinical study. Target population is patients with high-risk Soft tissue sarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with Liposome doxorubicin and Ifosfamide in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Key Dates

Start date
Oct 19, 2020
Status verified
Oct 2020
Primary completion
Oct 19, 2021
Completion
Mar 19, 2024

Study Design

Enrollment
62 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    camrelizumab in combination with Liposome doxorubicin and Ifosfamide intervention

Primary Outcome Measure

Objective response rate [ Time Frame: 24 months ]

Central Contacts

Related Studies